What is the appropriate promethazine‑dextromethorphan (Promethazine DM) dose for a child weighing 11.34 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Promethazine DM Should Not Be Used in This Child

Promethazine DM is contraindicated in children under 2 years of age, and strongly discouraged in children under 6 years old due to significant safety concerns including respiratory depression, sedation, and potentially life-threatening adverse events. 1 A child weighing 11.34 kg is likely under 2-3 years of age, placing them in the highest-risk category for serious complications.

Critical Safety Concerns

Age and Weight Considerations

  • Children weighing 11.34 kg are typically 12-24 months old, well below the minimum safe age for promethazine use 1
  • Promethazine has been associated with apparent life-threatening events (ALTEs) and possible sudden infant death syndrome (SIDS) in young children 1
  • The risk of adverse reactions is highest in children under 2 years of age who are most vulnerable to the drug's effects 1

Documented Adverse Events

  • Significant sedation, agitation, hallucinations, seizures, and dystonic reactions have been reported with promethazine use in pediatric patients 1
  • The combination product (with dextromethorphan) adds additional risks of central nervous system depression, ataxia, tachycardia, and autonomic symptoms 2
  • Dystonia occurred in 5.4% of pediatric dextromethorphan exposures in surveillance data 2

Alternative Approach

Supportive Care Recommendations

  • Cough medications are not recommended by the American Academy of Pediatrics for young children, as efficacy is uncertain and risks outweigh benefits 3
  • Supportive measures (hydration, humidified air, nasal saline) are the appropriate first-line approach for upper respiratory symptoms in this age group 3

If Medication Is Absolutely Required

  • No safe dose of Promethazine DM exists for this weight/age group - the product should not be prescribed 1
  • Consider age-appropriate alternatives only after careful risk-benefit assessment and consultation with a pediatric specialist 1

Common Pitfalls to Avoid

  • Do not assume over-the-counter status implies safety in young children - promethazine's prescription-only history reflects its significant risk profile 1
  • Liquid formulations increase inappropriate use in young children due to ease of administration 1
  • Weight-based dosing does not mitigate age-related contraindications - developmental factors make young children uniquely vulnerable regardless of calculated dose 1

References

2
Research

Adverse events associated with pediatric exposures to dextromethorphan.

Clinical toxicology (Philadelphia, Pa.), 2017

Related Questions

Can a 5-year-old take Robitussin (dextromethorphan) and ondansetron together?
Is Bromfed DM (Brompheniramine and Dextromethorphan) safe for 11 and 14 year old children?
Is Bromfed DM (dextromethorphan and pseudoephedrine) suitable for children?
Can dextromethorphan be given to a child under 4 years of age?
What is the recommended dosage for pediatric patients with coughs?
What is the appropriate first‑line treatment for uncomplicated cutaneous ringworm (tinea corporis, tinea cruris, or tinea pedis)?
Which marker provides a more accurate assessment of renal function, serum creatinine or cystatin C?
In a patient 15–20 days after a spontaneous intracerebral hemorrhage, can I administer extended‑release nicardipine 20 mg via the rectal route, given the risk of a sudden large blood‑pressure fall?
What supplement regimen should be used for a patient who has just started levodopa‑carbidopa therapy?
For a patient with hypertensive emergency and cerebral vasospasm receiving IV normal saline, when should the infusion be continued or discontinued, and what laboratory monitoring is required?
What is the appropriate management of pyoderma gangrenosum?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question